biologic

Vyvgart

efgartigimod alfa-fcab

Loss of exclusivityDecember 2033projected — 12-year biologic exclusivity estimate
CompanyArgenx BV

Drug detail

Brand nameVyvgart
Active ingredientefgartigimod alfa-fcab
Strength400MG/20ML (20MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalDecember 2021
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Vyvgart patent cliff — loss of exclusivity December 2033 | CliffBio